We reviewed consolidation therapy results and analyzed postremission outcomes for 1464 children less than 21 years old at diagnosis in five consecutive Children's Cancer Group acute myeloid leukemia trials between 1979 and 1996. Children in remission were allocated to allogeneic bone marrow transplantation (BMT) (N ¼ 373) in first remission, if a matched family donor was available. Remaining children were assigned consolidation chemotherapy (N ¼ 688) or autologous purged BMT (N ¼ 217), or withdrew from study before assignment, or with unknown data (N ¼ 186). Overall and disease-free survival were superior for children assigned allogeneic transplants. High (450 000/ll) diagnostic white blood cell (WBC) count was prognostic for inferior outcome, but French-American-British (FAB) subtypes were not. Inv (16) is a favorable karyotypic feature for children in first remission and t(8;21) is not. Allogeneic transplantation benefit was evident in most children, including those with high or low diagnostic WBC count, each FAB subtype, and t(8;21), but was not seen in children with inv(16). Therefore, these data suggest reserving matched related donor allogeneic transplantation for children with inv(16) for second remission, but not those with t(8;21). Leukemia (2005) 19, 965-970.
Introduction
In the last 25 years, we have seen marked improved survival of children and adolescents with acute myeloid leukemia (AML) when the ability to deliver extremely intensive chemotherapy is critical to eradication of leukemia cells. 1, 2 Although escalation of therapeutic intensity has been associated with more prolonged myelosuppression and immunosuppression, improvements in supportive care may have diminished morbidity and mortality of these complications, and contributed to better outcomes.
Since 1979, the Children's Cancer Group (CCG, now part of the Children's Oncology Group (COG)) has completed five prospective therapeutic trials for children with newly diagnosed AML (CCG-251, -213, -2861, -2891, and -2941 in chronological order). In each of these studies, remission was induced with intensive chemotherapy in 74-80% of children; those children who entered remission received consolidation consisting of chemotherapy, autologous bone marrow transplant (BMT) (in CCG-2861 and CCG-2891), or allogeneic hematopoietic stem cell transplantation. This report summarizes cumulative results of remission consolidation in these five CCG trials. Specifically, we compared outcomes of various postinduction treatments, investigated prognostic significance of karyotypes, diagnostic white blood cell (WBC) count, and French-American-British (FAB) subtypes, and we present data that bear upon the discussion of whether to transplant children in first remission who have cytogenetic abnormalities determined in other studies to be relatively favorable.
Methods

Patients and treatments
All children less than 21 years of age with AML who achieved remission on the five CCG studies were analyzed (N ¼ 1464), excluding children with acute promyelocytic leukemia (APL) (M3), myelodysplastic syndrome (MDS), or Down's syndrome (DS). The details of treatment have been reported and are summarized briefly in Table 1 . In all studies, children with related donors, matched at five or six of the six HLA-A, -B, and DR antigens, were allocated to allogeneic BMT. Histocompatibility was assessed by serological HLA typing and early on by mixed leukocyte culture. The remaining children were assigned to chemotherapy, except for those on CCG-2891, on which children who did not have matched family donors (MFD) were randomly allocated to receive consolidation chemotherapy or a 4-hydroperoxycyclophosphamide purged autologous BMT, or on CCG-2861, on which all children received allogeneic or autologous BMT.
Clinical characteristics of children who achieved remission are presented in Table 2 . Some data were not available for children on CCG-251, which accounts for the number of children in remission exceeding the total of the three regimens. Acute graft-versus-host disease (GVHD) was graded according to standard criteria. 3 Reporting of chronic GVHD was inconsistent in early studies and could not be evaluated. AML was classified according to FAB criteria. 4 Morphology, histochemistry, and karyotypes were centrally reviewed as reported. 5 All studies were reviewed and approved by the institutional review boards of participating CCG member institutions. Appropriate written informed consent/assent was obtained before children were entered, in accordance with the Declaration of Helsinki.
only included children with AML (excluded children with APL, DS, or MDS) who were in first remission at the end of induction on their respective studies.
The significance of observed differences in proportions was tested using the w 2 test and Fisher's exact test when data were sparse. The Mann-Whitney test was used to determine the significance between differences in medians. 6 The KaplanMeier method 7 was used to calculate estimates of overall survival (OS), defined as the time from achievement of remission at the end of induction therapy to death from any cause, and Some patients were entered on a pilot study of IL-2 after completion of chemotherapy on CCG-2941. disease-free survival (DFS), defined as the time from achievement of remission at the end of induction therapy to relapse or death from any cause. Cumulative incidence estimates were used to estimate the relapse risk (RR) and treatment-related mortality (TRM). 8 RR was defined as the cumulative incidence of relapse or death from progressive disease after remission, when nonprogressive disease-related death was a competing event. TRM was defined as the cumulative incidence of nonprogressive disease-related death after remission, when relapses and deaths from progressive disease were competing events. Children lost to follow-up were censored at their date of last known contact or at a cutoff 6 months before the date the data were frozen.
Since the primary interest was in long-term outcome and not, for example, the shape of the survival and cumulative incidence curves, comparisons of outcomes at 8 years were used. Differences in 8-year estimates were tested for significance using Wald statistics of differences in Kaplan-Meier estimates (for OS and DFS) and cumulative incidence estimates (for RR and TRM) that employed standard errors of Greenwood 9 and Gaynor et al, 10 respectively. Seven children who died without relapse and without information on the main cause of death were excluded from the analyses of RR and TRM. Differences in the cure fractions (ie long-term survival) for children with and without MFD, after adjusting for the study each child was enrolled on were tested for significance using multivariate nonmixture parametric cure regression models. Approximately 15% of children did not receive the regimen to which they were allocated. This was true for all studies and all regimens. However, all comparisons of regimens are reported as intent to treat.
Results
Comparison of outcomes for postinduction therapies
Children assigned allogeneic BMT had significantly better OS and DFS compared with those without an available MFD, after adjusting for the study each child was enrolled on ( Table 3) . The RR at 8 years for children assigned to allogeneic transplantation was significantly lower than that for children not having an MFD (3675 vs 5673%, Po0.001). There was no benefit of autologous transplantation compared with chemotherapy (Table 3) .
Among the 302 children with an MFD who had information on the donor source, 288 (95.4%) had a matched sibling donor and 14 (4.6%) had a matched parental donor. The 8-year TRM was significantly higher among children assigned allogeneic transplants than among children without an MFD available (1774 vs 772%, Po0.001) ( Table 3 ). This may have been related in part to complications of acute GVHD (aGVHD). Grades 1, 2, and 3/4 aGVHD were reported in 18, 15, and 13% of allogeneic transplanted recipients, respectively.
Effects of WBC, FAB, and karyotypes on outcomes
Among 1462 who had data on diagnostic WBC count available, 379 (25.9%) had WBC of at least 50 000/ml. Children with a high diagnostic WBC (at least 50 000/ml) have inferior postremission outcome compared with those with lower diagnostic WBC (8-year OS: 4375 vs 4873%, P ¼ 0.065; DFS: 3075 vs 4373%, Po0.001; and RR: 6375 vs 4773%, Po0.001). The benefit of allogeneic transplantation relative to chemotherapy is evident for children with high WBC and for children with lower WBC (Table 4, Figure 1 ).
FAB subtypes were available for 95.4% of the children ( Table 2 ). The most common subtypes were M1/M2 (51%), M4 (27%), and M5 (15%). None of the FAB subtypes were prognostic for outcome. However, there was a trend for inferior OS for children with FAB M6 or M7 (37711 vs 4873%, P ¼ 0.059). For each FAB subtype, children assigned allogeneic transplantation had superior outcome compared to those without an MFD. For example, children with FAB M1/M2 who had an MFD had an 8-year OS of 5678% compared with 4374% (P ¼ 0.004) for children with FAB M1/M2 who did not have an MFD. Withdrew from study prior to regimen assignment or unknown data. Cure regression P-values that adjust for WBC and the study each child was enrolled on.
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Among 753 children with available centrally reviewed and approved karyotype analyses on the leukemia cells (51%), 243 (32%) had normal karyotypes ( Table 2 ). The most common abnormalities were t(8;21) (12%), pseudodiploid (11%), 11q23 (8%), t(9;11) (7%), and inv(16) (7%). Inv(16) was the only karyotypic feature with significantly different outcomes compared with children with other karyotypic features ( Table 5 , Figures 2a and b) . Specifically, the children with inv(16) who were assigned allogeneic transplant (n ¼ 19) have superior 8-year OS compared with children without inv(16) assigned allogeneic transplant (79719 vs 5778%, P ¼ 0.028). Similarly, children with inv(16) without an MFD available (n ¼ 35) had superior 8-year OS (66716 vs 4074%, P ¼ 0.002), DFS (49717 vs 3374%, P ¼ 0.070), and RR (40717 vs 6074%, P ¼ 0.022) compared with children without inv(16) who did not have an MFD available.
For the children without an MFD available, it is noteworthy that children with t(8;21) had similar 8-year OS (42713 vs 4174%, P ¼ 0.938), DFS (34712 vs 3474%, P ¼ 0.991), and RR (58712 vs 5874%, P ¼ 0.967) compared to children without t (8;21) . Similarly, children with t(8;21) who were assigned allogeneic transplants had similar 8-year OS (58718 vs 5978%, P ¼ 0.909), DFS (55718 vs 5078%, P ¼ 0.616), and RR (23715 vs 3377%, P ¼ 0.201) compared to children without t(8;21) who were assigned allogeneic transplants.
The 8-year OS, DFS, RR, and TRM are similar for the inv(16) children with and without an available MFD (Table 5) . Conversely, for children with t(8;21) and normal karyotypes, those assigned allogeneic transplant have superior outcomes compared with those without an available MFD.
Discussion
The five consecutive CCG studies considered in this paper represent a large population of children accrued over nearly 20 years. Children assigned allogeneic transplantation had superior DFS, OS, and RR compared with those without an MFD, in spite of increased TRM associated with that therapy (Table 3 ). There was no benefit of autologous transplantation compared with chemotherapy (Table 3) .
Although the aggregate results for the CCG studies from 1979 to 1996 (Table 3) Figure 1 DFS from the end of induction by diagnostic WBC and MFD donor status for AML patients in first remission. 
P-values are from cure regression models that adjust for the study each child was enrolled on. a P-value corresponds to difference in 8-year estimates because cure regression model did not converge.
are comparable to that of BFM 93, MRC AML 10, and NOPHO 93. Specifically, children with an MFD enrolled on the intensive timing arm of CCG-2891 have 8-year estimates of OS 68%, DFS 59%, RR 31%, and TRM 10%, which are comparable to those with an MFD enrolled on BFM 93 (DFS 65%; RR 26%; TRM 10%), MRC AML 10 (OS 69%; DFS 70%; TRM 13%), and NOPHO 93 (DFS 79%; TRM 14%). Children assigned postinduction chemotherapy on the intensive timing arm of CCG-2891 have 8-year estimates of OS 56%, DFS 47%, RR 48%, and TRM 6%, which may be inferior to patients enrolled on BFM 93 (DFS 61%; RR 33%; TRM 4%) but are similar to those enrolled on MRC AML 10 (OS 59%; DFS 46%) and NOPHO 93 (DFS 47%). This study is limited by the retrospective nature of the analyses. The studies considered were not powered to investigate the prognostic significance of karyotypes, WBC, and FAB subtypes. Another limitation is that karyotypes were only available for 51% of the children. This study combines data from five studies conducted over nearly a 20-year period. During this time period in question, it is possible that patient characteristics differed and there were improvements in supportive care, chemotherapy, or salvage therapy. To reduce the potential for bias from such differences, multivariate regressions that adjusted for the study each child was enrolled on were used.
As AML survival has improved, identification of risk groups has become possible. Thus, children can be identified at diagnosis by risk of relapse and/or TRM. Two obvious subsets have sufficiently good prognoses that they are no longer transplanted in first remission: children with APL instead receive targeted therapy without transplantation and children with DS receive chemotherapy alone because transplantation caused excess toxicity without benefit. 15, 16 WBC count at diagnosis has long been considered a prognostic factor for children with AML. 17 Our data confirmed that children in first remission with high diagnostic WBC (450 000/ml) have inferior outcomes compared with those with lower WBC. Our data further suggest a benefit for MFD allogeneic transplantation for children in first remission regardless of their diagnostic WBC (Table 4, Figure 1 ).
Our data did not suggest a prognostic significance for any FAB subtype for children in first remission. However, there was a trend toward inferior outcome for those with FAB subtypes M6 or M7. The inferior outcome of children with FAB M7 has been reported previously. [18] [19] [20] The power to detect the prognostic significance of M0, M6, and M7 could be limited by the relatively small number of children with each of these subtypes. Despite this, our data did suggest a benefit for MFD allogeneic transplantation for children in first remission regardless of their FAB subtype.
Other prognostic criteria have been identified, including karyotypic markers, with favorable implications. Investigators have consistently observed better outcomes for children and adults with inv (16) . 17, [20] [21] [22] [23] [24] Most investigators have also observed better outcomes for those with t(8;21) than those without it, 17, [20] [21] [22] [23] but there has been one report of worse outcomes for children with t(8;21). 24 In our pediatric population, inv(16) also appears to confer a survival advantage for children with AML in first remission, but our data do not support t(8;21) as a favorable karyotypic risk feature for children with AML in first remission. We do not have any hypotheses for why the children with t(8;21) did not have better outcomes.
Karyotypic markers with unfavorable implications also have been identified, in particular, monosomy 5 and monosomy 7.
22,24 Our data do not suggest an inferior postremission outcome for the 28 children with abnormalities of chromosome 7 in first remission compared with children with other karyotypes in first remission. Only seven children had À5, a rare abnormality in children, so we were unable to draw any conclusions regarding prognostic significance of À5 for children with AML in first remission. This was also true for other infrequent abnormalities.
The question has been raised of whether children in first remission whose leukemia cells carry favorable chromosome markers will benefit from matched related donor allogeneic transplantation. 11, 25 Our data did not show a benefit of allogeneic transplant with respect to OS, DFS, or RR for children with inv(16) ( Table 5 ). Therefore, these data suggest that allogeneic transplants could be reserved for children with inv (16) and MFD in second remission. Conversely, our data showed a benefit of allogeneic transplant with respect to DFS and RR for children with t(8;21). Issues of quality of life and long-term complications of therapy (particularly transplantation) also may impact the decision of whether to transplant children in initial remission. Children with inv(16) and t(8;21) comprise a relatively small population. Therefore, their numbers would not permit a randomized prospective study. Thus, the decision of whether to transplant children with inv(16) and t (8;21) in first remission will be based on limited data.
The differences in the prognostic significance of karyotypes and the benefit of allogeneic transplant for children with t(8;21) compared to other studies may be explained by differences in therapy and differences in the populations treated. Unlike the BFM, MRC, and NOPHO studies, the CCG trials included patients up to the age of 21 years and a relatively high percentage of African American and Hispanic patients who tend to have inferior outcomes. 26 Since the prognostic significance of factors are related, in part, to the treatment given, the transplant policy in current COG AML studies will be based on the available data for therapy most similar to that in the study. Since the next COG phase III study will include therapy similar to the MRC AML12, which is most similar to therapy in MRC AML10, 2 for which it has been shown that there is no benefit to transplanting in first remission those with inv(16) or t(8;21), 27 the next COG phase III study is not planning on transplanting children with inv(16) and t(8;21) in first remission.
